newsfilter
← Latest News
PR Newswire·

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Initiation of Phase 2a Clinical Trial Expected to Occur in Q3 2023 BOSTON, May 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company on a quest to transform